Symbio LLC, a client-focused, full-service clinical research organization, has signed a five-year contract with OmniComm Systems, Inc., a global provider of clinical data management technology. Under the agreement, Symbio will use OmniComm’s TrialMaster version 5 to develop and manage clinical study databases.
Additonally, in 2018, Symbio launched its European operations to support clients with global trials. With the opening of that division, OmniComm’s data center in Europe became a major factor in the selection of TrialMaster. Symbio cited the stability and performance of OmniComm’s EDC technology, TrialMaster’s randomization capability, and the ability to create submission-ready CRFs, ad hoc reports, and customized reports to address sponsors’ needs and requests as contributing factors to its decision.
“We are honored and thrilled that the Symbio management team has selected OmniComm’s TrialMaster platform with its advanced EDC and eSource technology to enhance the services provided to their Sponsor clients,” said Kuno van der Post, PhD, chief commercial officer, OmniComm Systems. “To have another key global CRO choose TrialMaster is very rewarding.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.